Pancreas Transplantation Treatment & Management
- Author: Dixon B Kaufman, MD, PhD; Chief Editor: Ron Shapiro, MD more...
The timing of allocation of the pancreas to a specific patient relative to the procurement of the organ has important implications. Determining donor human leukocyte antigen (HLA) typing, serologies, and crossmatch results with patients on the pancreas transplantation waiting list will permit the ideal situation of allocating the cadaveric pancreas (plus kidney, with SPK transplantation) prior to procurement of the organs. This sequence of events has several advantages, as follows:
Prior allocation allows the transplantation center performing the pancreas transplantation the choice to procure the pancreas as well. It allows patients to be admitted to the hospital and the reevaluation process to begin simultaneously with the procurement of organs, rather than sequentially.
The cold-ischemia time of the pancreas prior to implantation is minimized. Pancreas allografts do not tolerate cold-ischemia as well as kidney allografts. Ideally, the pancreas should be revascularized within 24 hours from the time of cross-clamping at procurement.
Finally, prior allocation also allows identification of 0-antigen mismatched donor-recipient pairs before procurement, which minimizes cold-ischemia time if the organs need to be transported across country.
Pancreas transplantation surgery
The surgical techniques for pancreas transplantation are diverse, and no standard methodology is used by all programs. The principles are consistent, however, and include providing adequate arterial blood flow to the pancreas and duodenal segment, adequate venous outflow of the pancreas via the portal vein, and management of the pancreatic exocrine secretions. The native pancreas is not removed. Pancreas graft arterial revascularization typically is accomplished using the recipient right common or external iliac artery. The Y-graft of the pancreas is anastomosed end-to-side. Positioning of the head of the pancreas graft cephalad or caudad is not relevant with respect to successful arterial revascularization.
When the pancreas transplantation is performed simultaneously with kidney transplantation, it is not uncommon for the kidney transplantation to be performed first. The kidney is based on the recipient left iliac vessels. Both organs may be transplanted through a midline incision and placed intraperitoneal.
Occasionally, considering placement of pancreas transplantation based on the left iliac vessels is necessary because of previously placed kidney transplantation on the right side. In this sequential pancreas-after-kidney transplantation procedure, the intra-abdominal approach is used. Mobilization of the left iliac vessels medial to the sigmoid colon is somewhat more challenging.
Most programs have had good experience with enteric drainage of the pancreas transplantation alone. Markers for rejection include clinical signs and symptoms of pancreas graft pancreatitis and measurement of serum amylase or lipase levels coupled with biopsy. The pancreas is sometimes drained into the bladder if a pancreas transplantation alone or pancreas-after-kidney transplantation is performed in order to measure urinary amylase levels as a method of detecting rejection.
Two choices are available for venous revascularization—systemic and portal. No clinically relevant difference in glycemic control has been documented. Currently, approximately 15% of pancreas transplantations are performed with portal venous drainage and the remainder with systemic venous drainage.
Systemic venous revascularization commonly involves the right common iliac vein or the right external iliac vein following suture-ligation and division of the hypogastric veins.
If portal venous drainage is used, dissecting out the superior mesenteric vein (SMV) at the root of the mesentery is necessary. The pancreas portal vein is anastomosed end-to-side to a branch of the SMV. This may influence the methodology of arterial revascularization using a long Y-graft placed through a window in the mesentery to reach the right common iliac artery. Portal venous drainage of the pancreas is more physiologic with respect to immediate delivery of insulin to the recipient liver. This results in diminished circulating insulin levels relative to that in systemic venous-drained pancreas grafts.
Handling the exocrine drainage of the pancreas is the most challenging aspect of the transplantation procedure. Several methods exist. Very few programs use duct injection. Pancreatic exocrine drainage is handled by means of anastomosis of the duodenal segment to the bladder or anastomosis to the small intestine. Currently, approximately 80% of pancreas transplantations are performed with enteric drainage; the remaining 20% are performed with bladder drainage.
See the images below.
The bladder-drained pancreas transplantation was a very important modification introduced in about 1985. This technique significantly improved the safety of the procedure by minimizing occurrence of intra-abdominal abscess from leakage of enteric-drained pancreas grafts.
With the successful application of the new immunosuppressant agents and the reduction of the incidences of rejection, enteric drainage of the pancreas transplantations has enjoyed a successful rebirth. Enteric drainage of pancreas grafts is physiologic with respect to the delivery of pancreatic enzymes and bicarbonate into the intestines for reabsorption. Enterically drained pancreases can be constructed with or without a Roux-en-Y. The enteric anastomosis can be made side-to-side or end-to-side with the duodenal segment of the pancreas. The risk of intra-abdominal abscesses is extremely low, and avoidance of the bladder-drained pancreas has significant implications with respect to the potential complications that include the following: bladder infection, cystitis, urethritis, urethral injury, balanitis, hematuria, metabolic acidosis, and the frequent requirement for enteric conversion.
Following successful pancreas transplantation, no dietary restrictions are required. In fact, the diet can be liberalized to include virtually anything because blood sugar control is restored to normal.
Following successful pancreas transplantation, few activity restrictions are needed. Extreme contact sports probably should be avoided to prevent accidental trauma to the newly placed intra-abdominal organs.
Demartines N, Schiesser M, Clavien PA. An evidence-based analysis of simultaneous pancreas-kidney and pancreas transplantation alone. Am J Transplant. 2005 Nov. 5(11):2688-97. [Medline].
Burke GW 3rd, Vendrame F, Virdi SK, Ciancio G, Chen L, Ruiz P, et al. Lessons From Pancreas Transplantation in Type 1 Diabetes: Recurrence of Islet Autoimmunity. Curr Diab Rep. 2015 Dec. 15 (12):121. [Medline].
Kerr HR, Hatipoglu B, Krishnamurthi V. Pancreas transplant for diabetes mellitus. Cleve Clin J Med. 2015 Nov. 82 (11):738-44. [Medline].
Ziaja J, Bozek-Pajak D, Kowalik A, Krol R, Cierpka L. Impact of pancreas transplantation on the quality of life of diabetic renal transplant recipients. Transplant Proc. 2009 Oct. 41(8):3156-8. [Medline].
Decker E, Coimbra C, Weekers L, et al. A retrospective monocenter review of simultaneous pancreas-kidney transplantation. Transplant Proc. 2009 Oct. 41(8):3389-92. [Medline].
Becker LE, Hallscheidt P, Schaefer SM, Klein K, Grenacher L, Waldherr R, et al. A Single-center Experience on the Value of Pancreas Graft Biopsies and HLA Antibody Monitoring After Simultaneous Pancreas-Kidney Transplantation. Transplant Proc. 2015 Oct. 47 (8):2504-12. [Medline].
Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant. 2015 Feb. 20 (1):94-102. [Medline].
McCullough KP, Keith DS, Meyer KH, Stock PG, Brayman KL, Leichtman AB. Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant. 2009 Apr. 9(4 Pt 2):894-906. [Medline].
Sampaio MS, Poommipanit N, Cho YW, Shah T, Bunnapradist S. Transplantation with pancreas after living donor kidney vs. living donor kidney alone in type 1 diabetes mellitus recipients. Clin Transplant. 2010 Nov. 24(6):812-20. [Medline].
Schenker P, Vonend O, Krüger B, Klein T, Michalski S, Wunsch A, et al. Long-term results of pancreas transplantation in patients older than 50 years. Transpl Int. 2011 Feb. 24(2):136-42. [Medline].
Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA, et al. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant. 2008 Jun. 8(6):1237-49. [Medline].
Drachenberg CB, Torrealba JR, Nankivell BJ, Rangel EB, Bajema IM, Kim DU, et al. Guidelines for the Diagnosis of Antibody-Mediated Rejection in Pancreas Allografts-Updated Banff Grading Schema. Am J Transplant. 2011 Aug 3. [Medline].
Browne S, Gill J, Dong J, Rose C, Johnston O, Zhang P, et al. The Impact of Pancreas Transplantation on Kidney Allograft Survival. Am J Transplant. 2011 Jul 12. [Medline].
Mora M, Ricart MJ, Casamitjana R, Astudillo E, López I, Jiménez A, et al. Pancreas and kidney transplantation: long-term endocrine function. Clin Transplant. 2010 Nov. 24(6):E236-40. [Medline].
Ojo AO, Meier-Kriesche HU, Hanson JA, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation. 2001 Jan 15. 71(1):82-90. [Medline].
Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant. 2005 Aug. 19(4):433-55. [Medline].
United Network for Organ Sharing (UNOS). United Network for Organ Sharing (UNOS). [Full Text].